Mariarosa Pascale, Cinzia Aversa, Renzo Barbazza, Barbara Marongiu, Salvatore Siracusano, Flavio Stoffel, Sando Sulfaro, Enrico Roggero, Serena Bonin and Giorgio Stanta
those markers, has been associated with disease progression 4 or poor survival in prostate cancer 5 , but up to now its prognostic value has not been clarified because of controversial results 6 ; 7 , 8 . However, Epstein et al. 9 have recently suggested using neuroendocrine markers to better characterize and classify NED in prostate cancer. They also outlined Ki67 ranges in those tumors, which usually have a high proliferative index. 4 , 9 - 13 Ki67 is a well-known marker in oncology for defining tumor proliferation. Expression of Ki67 detection by
Fulop Emoke, Coşarcă Adina, Păcurar Mariana, Ormenişan Alina, Monea Adriana, R Grigoraş and Mocan Simona
, Inderpreet Kaur, and Shalabh Srivastava, Analysis of the immunoexpression of Ki-67 and Bcl-2 in the pericoronal tissues of impacted teeth, dentigeous cysts and gingiva using software image analysis, Dent Res J (Isfahan), 2013; 10:31-37.
6. Ozveren A, Tuskan C, Yaltirik M, Et all. Expresion or the tumor suppresor gene p53 in odontogenic cyst. Turk J Med Sci, 2003; 33:243-247.
7. Maryam Seyedmajidi, Shima Nafarzadeh, Sepideh Siadati, Shahryar Shafaee, Ali Bijani, Nazanin Kehmiri, p53 and PCNA expressin in Keratocystic odontogenic tumors compared with Selected
. Cancer. 2015;121:1499-507.
17. Kee N, Sivalingam S, Boonstra R, Wojtowicz JM. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods. 2002;115:97-105.
18. Yuan Y, Xiang W, Yanhui L, Ruofei L, Shuang L, Yingjun F, Qiao Z, Yanwu Y, Qing M. Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control. Seizure. 2013;22:877-81.
19. Wu Z, Wang Q, Wang L, Li G, Liu H, Fan F, Li Z, Li Y, Tu Y. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma
Ioan-Mihai Japie, Dragoș Rădulescu, Adrian Bădilă, Alexandru Papuc, Traian Ciobanu, Adrian Dumitru and Cătălin Cîrstoiu
1. Von Eisenhart-Rothe R, Toepfer A, Salzmann M, Schauwecker J, Gollwitzer H, Rechl H. Primary malignant bone tumors. Orthopade. 2011 Dec; 40(12):1121-42.
2. Majid C, Keith H, Lee J. Primary malignant tumours of the bone. Surgery. 2009 February; 27(2):80-85.
3. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Proliferation. 1992 January; 25(1):31–40.
4. Hernández-Rodríguez NA, Correa E, Sotelo R, Contreras-Paredes A, Gomez-Ruiz C, Green
Adem Karaman, Irmak Durur-Subasi, Fatih Alper, Omer Araz, Mahmut Subasi, Elif Demirci, Mevlut Albayrak, Gökhan Polat, Metin Akgun and Nevzat Karabulut
: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35.
9. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.
10. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
11. Raĭkhlin NT, Bukaeva IA, Smirnova EA, Gurevich LE, Delektorskaia VV, Polotskiĭ BE, et al. Significance of the expression of nucleolar argyrophilic
Małgorzata Kandefer-Gola, Rafał Ciaputa, Marcin Nowak and Janusz A. Madej
1. Agoff S.N., Lin P., Morihara J., Mao C., Kiviat N.B., Koutsky L.A.: p16INK4a expression correlates with degree of cervical neoplasia: A comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003, 16 , 665-673.
2. Barnard N.J., Hall P.A., Lemoine N.R., Kadar N.: Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987, 152 , 287-295.
3. Beaumont P.R., O’Brien J
Telomerase Activity and MDS/EVI Gene Fusion in Myelodysplastic Syndrome. Correlation to the Immunohistochemical Expression of Ki-67, Bcl-2 and p53 in Bone Marrow Biopsy Samples
Background. Myelodysplastic syndrome (MDS) as a complex disorder comprised of 7 entities may arise as a primary disorder, or in a setting of an underlying disease, or as therapy related (secondary MDS). Some cases show MDS/EVI1 gene fusion, and some studies have pinpointed the association between the high-risk MDS and increased telomerase activity.
Aim. To determine the frequency of MDS/EVI1 gene fusion in cases of primary MDS, and to evaluate the possibility for detection of increased telomerase activity in peripheral blood samples from patients with MDS.
Material and methods. We isolated DNA from 35 bone marrow biopsies, and measured the blood telomerase activity (RTA) in 21 of the patients. We performed immunostainigs for Ki-67, Bcl-2 and p53 on the biopsy samples in order to test the correlations to the RTA and MDS/EVI1 presence. MDS/EVI1 fusion was detected with touch-down-direct PCR, and RTA was measured using the "TeloTAGGG-PCR-ELISA-plus kit".
Results. We found MDS/EVI1 fusion in 17.39% of high-risk MDS cases (overall 11.43%). RTA was highly variable in the analyzed group, with 1,8 fold increase of the mean RTA compared to the controls. It was due to the significant RTA increase in high-risk MDS cases, compared to the low-risk cases (p<0.01).
Conclusion. RTA showed correlation to the immunohistochemical expression of Ki-67, and MDS/EVI1 fusion was correlated to the Bcl-2 expression.
Ciortea Carmen Diana, Gurzu Simona, Zdrob Simona Maria and Jung I
. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35:215-221.
18. de Giorgi V, Gori A, Grazzini M, et al. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther. 2011;11:739-747.
19. Vaisanen A, Kuvaja P, Kallioinen M, et al. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol. 2011;42:1103-1111.
20. Helfrich I, Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic
G. et al. Medullary thyroid carcinoma. In: Pathology and genetics of tumors of endocrine system. World Health Organization Classification of Tumors, IARC, Lyon: IARC Press. 2001; 86-91.
7. Cobanoglu B, Ozercan M.R. Staining characteristics of BCL-2, BAX, p53, p21, Ki-67 andC-erbB2 in thyroid carcinomas. Erciyes Medical Journal 2007; 29 (3): 201-209.
8. Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, et al.: Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol. 1995; 26(9): 945